StreetInsider.com News Articles

Beam Therapeutics names Eric Foster as chief commercial officer

Tue, 01 Sep 2026 07:00:29 -0400

Beam Therapeutics Inc. (Nasdaq: BEAM) has appointed Eric Foster as chief commercial officer, the Cambridge, Mass.-based biotechnology company announced.

Foster brings more than 25 years of commercial experience in biotechnology and specialty pharmaceuticals. He most recently served as chief commercial officer at Ardelyx. Before that, he was senior vice president and U.S. general manager at Amgen, a role he assumed following Amgen's acquisition of Horizon Therapeutics in October 2023.

At Horizon, Foster served as senior vice president and general manager of the gout and ophthalmology business units, overseeing franchises that generated $2.75 billion in net sales revenue. From 2010 to 2021, he

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

Tue, 01 Sep 2026 07:00:00 -0400

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.

“Eric is an exceptional biopharmaceutical leader with a proven track record of building high-performing commercial organizations in specialty and rare disease markets,” said John Evans, chief executive officer of Beam Therapeutics. “His decades of commercial leadership are

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

Tue, 01 Sep 2026 07:00:00 -0400

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Mon, 31 Aug 2026 07:00:00 -0400

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:

Wells Fargo 21^st Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York

The live

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Mon, 31 Aug 2026 07:00:00 -0400

Wells Fargo 21^st Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York

The live

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Mon, 31 Aug 2026 07:00:00 -0400

Wells Fargo 21^st Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York

The live

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Mon, 31 Aug 2026 07:00:00 -0400

Wells Fargo 21^st Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York

The live

H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Tue, 25 Aug 2026 06:58:36 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst commented: "On August 20, we hosted an H.C. Wainwright At Home virtual fireside chat with Beam Therapeutics President and CEO John Evans, focused on BEAM-302 in alpha-1 antitrypsin deficiency (AATD), risto-cel in sickle cell disease (SCD), and the FDA-cleared BEAM-304 umbrella investigational new drug application (IND) in phenylketonuria (PKU). In AATD, the goal includes moving ZZ patients from mid-single-digit total alpha-1 antitrypsin (AAT) composed almost entirely of mutant Z protein into double-digit AAT with an inverted M:Z ratio and preserved

Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: ARK Investment Management LLC

Fri, 14 Aug 2026 14:56:00 -0400

si-local-file:///var/storage/secattach/20260814/26929246.html

Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: ARK Investment Management LLC

Fri, 14 Aug 2026 14:56:00 -0400

si-local-file:///var/storage/secattach/20260814/26929246.html

Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260813/26922695.html

Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260813/26922695.html

H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Mon, 10 Aug 2026 06:43:04 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst commented: "On August 4, Beam reported 2Q26 results and disclosed that in July it dosed the first patient in the global pivotal cohort of the ongoing Phase 1/2 trial evaluating BEAM-302 in patients with AATD-associated lung disease, with or without liver disease, in a cohort designed to support a potential accelerated approval path in the U.S. (link to deck). Detailed and updated BEAM-302 clinical data were selected for a late-breaking oral presentation at the European Respiratory Society (ERS) Congress, September

Beam Therapeutics Inc (BEAM) PT Raised to $240 at JPMorgan

Wed, 05 Aug 2026 08:11:50 -0400

JPMorgan analyst Brian Cheng raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $240.00 (from $225.00) while maintaining a Overweight rating.

Beam, Inc. (BEAM) Misses Q2 EPS by 8c

Tue, 04 Aug 2026 07:14:30 -0400

Beam, Inc. (NASDAQ: BEAM) reported Q2 EPS of ($1.18), $0.08 worse than the analyst estimate of ($1.10). Revenue for the quarter came in at $490 thousand versus the consensus estimate of $15.88 million.

For earnings history and earnings-related data on Beam, Inc. (BEAM) click here.

Form 10-Q Beam Therapeutics Inc. For: Jun 30

Tue, 04 Aug 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260804/26861495.html

Form 10-Q Beam Therapeutics Inc. For: Jun 30

Tue, 04 Aug 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260804/26861495.html

Form 8-K Beam Therapeutics Inc. For: Aug 04

Tue, 04 Aug 2026 07:09:00 -0400

si-local-file:///var/storage/secattach/20260804/26861459.html

Form 8-K Beam Therapeutics Inc. For: Aug 04

Tue, 04 Aug 2026 07:09:00 -0400

si-local-file:///var/storage/secattach/20260804/26861459.html

Beam Therapeutics posts Q2 loss, doses first patient in BEAM-302 trial

Tue, 04 Aug 2026 07:00:17 -0400

Beam Therapeutics (Nasdaq: BEAM) reported a net loss of $122.7 million, or $1.18 per share, for the second quarter of 2026, compared to a net loss of $102.1 million, or $1.00 per share, for the same period in 2025, according to a company press release.

The Cambridge, Mass.-based biotechnology company said it dosed the first patient in the global pivotal cohort of its ongoing Phase 1/2 trial evaluating BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD). The cohort is designed to support a potential accelerated approval path in the United States.

Updated clinical data for BEAM-302 were selected for a late-breaking oral

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Tue, 04 Aug 2026 07:00:00 -0400

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026

Clinical Trial Start-up Activities Underway Following U.S. FDA Clearance of Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU)

Ended Second Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Tue, 04 Aug 2026 07:00:00 -0400

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026

Clinical Trial Start-up Activities Underway Following U.S. FDA Clearance of Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU)

Ended Second Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Tue, 04 Aug 2026 07:00:00 -0400

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026

Clinical Trial Start-up Activities Underway Following U.S. FDA Clearance of Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU)

Ended Second Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Tue, 04 Aug 2026 07:00:00 -0400

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026

Clinical Trial Start-up Activities Underway Following U.S. FDA Clearance of Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU)

Ended Second Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into

Form 4 Beam Therapeutics Inc. For: Jul 27 Filed by: Simon Amy

Wed, 29 Jul 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260729/26834871.html